T.TO 0.13ENB.TO 0.8BEP.UN.TO -1.15CP.TO 1.15VRT -19.67NVDA -7.33TSM -15.23JPM -6.1
Pfizer Inc (PFE)

NYSE:PFE

Pfizer Inc (PFE)

27.72
-0.00 (0.00%)
as of Sep 14, 2026, 8:00:00 pm Market Open.
583 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconSep 14, 2026, 12:00 am

This summary was created by AI, based on 27 opinions in the last 12 months.

Pfizer Inc. (PFE) is perceived as a defensive stock with an attractive dividend yield around 6-7%, appealing to income-focused investors. However, many experts express concern about the company's growth potential following a reliance on COVID-19 vaccine revenues, which have receded. The consensus indicates that while PFE maintains a low valuation (PE around 8-10x), its growth is stagnant or uncertain due to impending patent expirations and the challenges associated with developing new blockbuster drugs. Moreover, there are worries that the ongoing focus on acquisitions may not lead to the anticipated revenue boosts. Despite these concerns, some analysts suggest PFE could still perform well for patient investors, especially as sector interest begins to build. Ultimately, the outlook remains cautious, with a preference noted for other stocks in the pharmaceutical sector that exhibit better growth trajectories.

consensus icon
Consensus
Cautious
valuation icon
Valuation
Undervalued
review icon
Similar
LLY
DON'T BUY

Pfizer Inc(PFE)

Jul 24, 2007
Has been a very frustrating stock to have. Doesn't seem to be able to get out of its own way.
Photo of Brendan CaldwellBrendan Caldwell
Owned
Unlock Rating
$24.89

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

Jul 18, 2007
Just reported numbers that were a little bit lighter than expectations. They also reaffirmed their view for next year that they expect to make back the shortfall later in the year. This knee-jerk reaction is an opportunity. 4.5% new.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$25.13

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Jul 17, 2007
Doesn't like the business models of pharmaceutical companies. Can be hit by generics, lawsuits, etc.. Prefers business models with downside protection. After the next US election, expect there will be severe regulations on pharmaceutical prices.
Photo of Pat NaccaratoPat Naccarato
No
Unlock Rating
$25.96

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Jul 17, 2007
A pure pharmaceutical play and he cautious on this sector. Concerned about lawsuits, patent litigations on generic drugs and also patent expiries.
Photo of David BaskinDavid Baskin
No
Unlock Rating
$25.96

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Jun 21, 2007
The model price is $42, a 63% positive differential. All the drug companies are moving, except this one. Huge cash flows. 5% dividend yield.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$25.92

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Jun 07, 2007
47% positive differential. The most mispriced in the Dow Jones. bonus of 5% dividend yield. They are in around $26.63.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$26.29

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

May 24, 2007
(A Top Pick July 21/06. Up 14.5%.) 5% yield. His model price is $48.51, a 52% positive differential. The cheapest stock in the Dow Jones.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$27.28

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
COMMENT

Pfizer Inc(PFE)

May 16, 2007
Is preforming quite well without a lot of fanfare. Thinks it is going to trade to a discount, would rather go to a Sheering or Abbot.
Photo of David BurrowsDavid BurrowsUnlock Rating
$27.32

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

May 02, 2007
Hasn't moved but has the most value of similar stocks. Massively mispriced.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$26.60

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
COMMENT

Pfizer Inc(PFE)

May 01, 2007
Blue chip. Nice dividend. Don't expect too much excitement.
Photo of Michael SmedleyMichael SmedleyUnlock Rating
$26.59

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

May 01, 2007
(A Top Pick May 9/06. Up 4.2%.) Yield gave him another 4%. Sold their consumers products division for $19 billion so have a huge amount of cash on the books. Can't see a lot of downside here.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$26.59

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Apr 26, 2007
Has value characteristics which is positive, but he can't get comfortable with their largest drug Lipidor going off patent in 2011. Does not all they'll make up for this.
Photo of Pat NaccaratoPat Naccarato
No
Unlock Rating
$26.72

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Apr 16, 2007
His value drug play. Growth drug play is Teva Pharmaceutical (TEVA-Q). Pharmaceuticals got the wind kicked out of them a couple of years ago and are now showing some rebound. Very nice yield. Huge cash hoard and are buying back stock and probably will increase dividends again.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$26.94

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
BUY ON WEAKNESS

Pfizer Inc(PFE)

Apr 16, 2007
Looks like it is in the process of breaking the downtrend. That was established with the recent higher lows. If you own, he would Hold.
Photo of John ManleyJohn ManleyUnlock Rating
$26.94

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Apr 12, 2007
(A Top Pick May 10/06. Up 5.3%.) One of the cheapest stocks on the S&P500. His model price is $40.47 giving it a 55% positive differential. Any positive catalyst will help the stock price. Dividends are almost 5%.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$26.46

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
Showing 571 to 585 of 890 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

TPZ.TO 0.13$12.73
KBL.TO 0.98$42.9
PPL.TO -0.14$66.12
AQN.TO 0.11$7.46
EMA.TO -0.02$68.17

Today's Top Picks

T.TO 0.13$12.73
ENB.TO 0.8$67.03
BEP.UN.T… -1.15$40.98
CP.TO 1.15$124.99
VRT -19.67$237.39

Popular Articles

Latest Sell Signals

CPX.TO 1.15$124.99
AVGO -17.27$344.72
APP 10.28$334.24
XRE.TO 0.05$15.73
ORCL -5.49$144.79

Most Recent Experts

Ryan Bushell

Ryan Bushell

Newhaven Asset Management

Liz Young, Head of investment strategy at SoFi

Liz Young, Head of investment strategy at SoFi

SoFi

Stephen Weiss, Founder, Short Hills Capital Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Jim Lebenthal

Jim Lebenthal

Cerity Partners

Joe Terranova

Joe Terranova

Virtus Investment Partners

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica
The ultimate 360° Tracker Your financial life in one place, automatically

You may also like